中国药物应用与监测
中國藥物應用與鑑測
중국약물응용여감측
CHINESE JOURNAL OF DRUG APPLICATION AND MONITORING
2014年
4期
198-200
,共3页
依达拉奉%脑梗死%肌酐%尿素氮%肾功能
依達拉奉%腦梗死%肌酐%尿素氮%腎功能
의체랍봉%뇌경사%기항%뇨소담%신공능
Edaravone%Cerebral infarction%Creatinine%Urea nitrogen%Renal function
目的：观察依达拉奉对脑梗死患者肾功能指标肌酐（Cr）和尿素氮（BUN）的影响。方法：选取2013年1-9月我院收治的脑梗死住院患者，共计130例，将其随机分为治疗组和对照组，每组65例，两组均采用脑梗死常规治疗。治疗组在常规治疗基础上加用依达拉奉注射液30 mg静脉滴注，分别于用药前、用药后第5天、第10天测定Cr和BUN值，对照分析用药前后肾功能指标Cr和BUN的变化情况。结果：两组患者治疗后Cr值呈明显下降趋势，第10天组间比较有显著性差异（P<0.05）。其中9例脑梗死伴肾功能不全者使用依达拉奉后第5天Cr值呈明显下降趋势，与治疗前相比，有显著性差异（P<0.05），但组间比较无显著差异（P>0.05）；治疗组BUN值呈上升趋势，组间与组内比较，差异均无统计学意义（P>0.05）。治疗组治疗后神经功能缺损程度评分（NDS）明显低于对照组（P<0.05），其显效率（69.6%）高于对照组（41.4%）（P<0.05）。治疗组有8例出现转氨酶轻微升高，16例BUN值升高；对照组有10例出现转氨酶轻微升高，8例BUN值升高，给予对症治疗后均好转。结论：本研究显示依达拉奉可降低脑梗死患者的肾功能指标Cr值，对BUN值无明显影响，但由于本文入选样本量少，观察时间短，其结论仍有待进一步考证。
目的：觀察依達拉奉對腦梗死患者腎功能指標肌酐（Cr）和尿素氮（BUN）的影響。方法：選取2013年1-9月我院收治的腦梗死住院患者，共計130例，將其隨機分為治療組和對照組，每組65例，兩組均採用腦梗死常規治療。治療組在常規治療基礎上加用依達拉奉註射液30 mg靜脈滴註，分彆于用藥前、用藥後第5天、第10天測定Cr和BUN值，對照分析用藥前後腎功能指標Cr和BUN的變化情況。結果：兩組患者治療後Cr值呈明顯下降趨勢，第10天組間比較有顯著性差異（P<0.05）。其中9例腦梗死伴腎功能不全者使用依達拉奉後第5天Cr值呈明顯下降趨勢，與治療前相比，有顯著性差異（P<0.05），但組間比較無顯著差異（P>0.05）；治療組BUN值呈上升趨勢，組間與組內比較，差異均無統計學意義（P>0.05）。治療組治療後神經功能缺損程度評分（NDS）明顯低于對照組（P<0.05），其顯效率（69.6%）高于對照組（41.4%）（P<0.05）。治療組有8例齣現轉氨酶輕微升高，16例BUN值升高；對照組有10例齣現轉氨酶輕微升高，8例BUN值升高，給予對癥治療後均好轉。結論：本研究顯示依達拉奉可降低腦梗死患者的腎功能指標Cr值，對BUN值無明顯影響，但由于本文入選樣本量少，觀察時間短，其結論仍有待進一步攷證。
목적：관찰의체랍봉대뇌경사환자신공능지표기항（Cr）화뇨소담（BUN）적영향。방법：선취2013년1-9월아원수치적뇌경사주원환자，공계130례，장기수궤분위치료조화대조조，매조65례，량조균채용뇌경사상규치료。치료조재상규치료기출상가용의체랍봉주사액30 mg정맥적주，분별우용약전、용약후제5천、제10천측정Cr화BUN치，대조분석용약전후신공능지표Cr화BUN적변화정황。결과：량조환자치료후Cr치정명현하강추세，제10천조간비교유현저성차이（P<0.05）。기중9례뇌경사반신공능불전자사용의체랍봉후제5천Cr치정명현하강추세，여치료전상비，유현저성차이（P<0.05），단조간비교무현저차이（P>0.05）；치료조BUN치정상승추세，조간여조내비교，차이균무통계학의의（P>0.05）。치료조치료후신경공능결손정도평분（NDS）명현저우대조조（P<0.05），기현효솔（69.6%）고우대조조（41.4%）（P<0.05）。치료조유8례출현전안매경미승고，16례BUN치승고；대조조유10례출현전안매경미승고，8례BUN치승고，급여대증치료후균호전。결론：본연구현시의체랍봉가강저뇌경사환자적신공능지표Cr치，대BUN치무명현영향，단유우본문입선양본량소，관찰시간단，기결론잉유대진일보고증。
Objective:To observe effect of edaravone on renal function indexes of blood creatinine (Cr) and urea nitrogen (BUN) in patients with cerebral infarction. Methods:A total of 130 inpatients with cerebral infarction from January to September in 2013 were collected and randomly divided into treatment group (n=65) and control group (n=65). All patients of two groups were given routine treatment for cerebral infarction. The patients in treatment group were added intravenously edaravone 30 mg besides routine treatment. The values of Cr and BUN were examined respectively before and on the 5th, 10th day after treatment. Indexes of the renal function were compared between the two groups. Results:Cr values of the both groups decreased signiifcantly after treatment. Cr values of treatment group decreased more signiifcantly compared with that of the control group on the 10th day (P<0.05). Cr values also signiifcantly decreased among 9 patients of cerebral infarction with renal insufifciency after the treatment of edaravone for 5 days (P<0.05), but showed no signiifcant differences compared between two groups (P>0.05);BUN values showed increased trend in treatment group, no signiifcant differences were found between or within groups (P>0.05). The neurologic deifcit scale (NDS) of the patients in treatment group was obviously lower than that of the control group (P<0.05), and the efifciency rate (69.6%) in treatment group was obviously higher than that of the control group (41.4%) (P<0.05). About 8 cases of elevated aminopherase and 16 cases of elevated BUN values were observed in treatment group, while 10 cases of elevated aminopherase and 8 cases of elevated BUN in control group. Conclusion:Edaravone could decrease the renal function index of Cr in patients with cerebral infarction, but had no obvious effect on BUN values, which should be authenticated by many samples, long-term observation and high quality study.
